Biorithm, a Singapore- Cambridge, MA-based women’s health medtech company, raised $3.5M in Series A funding.
The round was led by Adaptive Capital Partners and SEEDS Capital.
The company intends to use the funds to accelerate its expansion in Southeast Asia and the United States, advance Femom, a comprehensive obstetric remote monitoring solution, and complete clinical studies to support a 510(K) premarket submission to the US Food and Drug Administration.
Led by Amrish Nair, Founder and CEO, Biorithm has developed a remote maternal-fetal care platform with novel intellectual property in device and algorithms. Having grown from academia, Biorithm is now present globally, working with clinical partners to deliver care for mothers and babies. Its Femom is patient-friendly technology that facilitates patient monitoring, accessible personalized guidance, and seamless integration of predictive analytics that help clinicians to identify early signs of complication.
FinSMEs
18/12/2023